{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:21:45Z","timestamp":1790000505070,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["FKZ-IIA5-2513DSM228"],"award-info":[{"award-number":["FKZ-IIA5-2513DSM228"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40360-017-0183-0","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T12:13:07Z","timestamp":1512389587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["High prevalence of prescription of psychotropic drugs for older patients in a general hospital"],"prefix":"10.1186","volume":"18","author":[{"given":"Inken","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Himmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Heyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hummers-Pradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-995X","authenticated-orcid":false,"given":"Roland","family":"Nau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"key":"183_CR1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/MLR.0b013e31826ec185","volume":"50","author":"RR Aparasu","year":"2012","unstructured":"Aparasu RR, Chatterjee S, Mehta S, Chen H. Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents. Med Care. 2012;50:961\u20139.","journal-title":"Med Care"},{"key":"183_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12877-017-0428-1","volume":"17","author":"H Cioltan","year":"2017","unstructured":"Cioltan H, Alshehri S, Howe C, Lee J, Fain M, Eng H, et al. Variation in use of antipsychotic medications in nursing homes in the United States: a systematic review. BMC Geriatr. 2017;17:32. 10.1186\/s12877-017-0428-1 .","journal-title":"BMC Geriatr"},{"key":"183_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1192\/bjp.bp.112.122499","volume":"205","author":"T Gerhard","year":"2014","unstructured":"Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205:44\u201351. 10.1192\/bjp.bp.112.122499 .","journal-title":"Br J Psychiatry"},{"key":"183_CR4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/gerona\/60.5.622","volume":"60","author":"F Landi","year":"2005","unstructured":"Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R, Silver Network Home Care Study Group. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci. 2005;60:622\u20136.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"183_CR5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3325\/cmj.2011.52.16","volume":"52","author":"M Petek \u0160ter","year":"2011","unstructured":"Petek \u0160ter M, Cedilnik Gorup E. Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study. Croat Med J. 2011;52:16\u201324.","journal-title":"Croat Med J"},{"key":"183_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiat. 2015;72:438\u201345. 10.1001\/jamapsychiatry.2014.3018 .","journal-title":"JAMA Psychiat"},{"key":"183_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/jgs.13326","volume":"63","author":"Y Park","year":"2015","unstructured":"Park Y, Franklin JM, Schneeweiss S, Levin R, Crystal S, Gerhard T, Huybrechts KF. Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness. J Am Geriatr Soc. 2015;63:516\u201323. 10.1111\/jgs.13326 .","journal-title":"J Am Geriatr Soc"},{"key":"183_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1503\/cmaj.061250","volume":"176","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627\u201332. 10.1503\/cmaj.061250 .","journal-title":"CMAJ"},{"key":"183_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/11599460-000000000-00000","volume":"29","author":"AR Huang","year":"2012","unstructured":"Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29:359\u201376. 10.2165\/11599460-000000000-00000 .","journal-title":"Drugs Aging"},{"key":"183_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","volume":"80","author":"EA Davies","year":"2015","unstructured":"Davies EA, O\u2019Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80:796\u2013807. 10.1111\/bcp.12596 .","journal-title":"Br J Clin Pharmacol"},{"key":"183_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/ageing\/aft114","volume":"43","author":"CG McMahon","year":"2014","unstructured":"McMahon CG, Cahir CA, Kenny RA, Bennett K. Inappropriate prescribing in older fallers presenting to an Irish emergency department. Age Ageing. 2014;43:44\u201350. 10.1093\/ageing\/aft114 .","journal-title":"Age Ageing"},{"key":"183_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2318-14-40","volume":"14","author":"V Milos","year":"2014","unstructured":"Milos V, Bondesson \u00c5, Magnusson M, Jakobsson U, Westerlund T, Midl\u00f6v P. Fall risk-increasing drugs and falls: a cross-sectional study among elderly patients in primary care. BMC Geriatr. 2014;14:40. 10.1186\/1471-2318-14-40 .","journal-title":"BMC Geriatr"},{"key":"183_CR13","doi-asserted-by":"publisher","unstructured":"Puustinen J, Nurminen J, L\u00f6pp\u00f6nen M, Vahlberg T, Isoaho R, R\u00e4ih\u00e4 I, Kivel\u00e4 SL. Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study. BMC Geriatr. 2011;(1):70. 10.1186\/1471-2318-11-70 .","DOI":"10.1186\/1471-2318-11-70"},{"key":"183_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000336710","volume":"2","author":"J Puustinen","year":"2012","unstructured":"Puustinen J, Nurminen J, Vahlberg T, Lyles A, Isoaho R, R\u00e4ih\u00e4 I, Kivel\u00e4 SL. CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. Dement Geriatr Cogn Dis Extra. 2012;2:57\u201368. 10.1159\/000336710 .","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"183_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10072-016-2732-5","volume":"38","author":"A Federico","year":"2017","unstructured":"Federico A, Tamburin S, Maier A, Faccini M, Casari R, Morbioli L, Lugoboni F. Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study. Neurol Sci. 2017;38:137\u201342. 10.1007\/s10072-016-2732-5 .","journal-title":"Neurol Sci"},{"key":"183_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/ j.euroneuro.2012.05.004","volume":"23","author":"T Mura","year":"2013","unstructured":"Mura T, Proust-Lima C, Akbaraly T, Amieva H, Tzourio C, Chevassus H, et al. Chronic use of benzodiazepines and latent cognitive decline in the elderly: results from the three-city study. Eur Neuropsychopharmacol. 2013;23:212\u201323. 10.1016\/ j.euroneuro.2012.05.004 .","journal-title":"Eur Neuropsychopharmacol"},{"key":"183_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2012.211266","volume":"309","author":"BA Briesacher","year":"2013","unstructured":"Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. Antipsychotic use among nursing home residents. JAMA. 2013;309:440\u20132. 10.1001\/jama.2012.211266 .","journal-title":"JAMA"},{"key":"183_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archinternmed.2009.469","volume":"170","author":"Y Chen","year":"2010","unstructured":"Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170:89\u201395.","journal-title":"Arch Intern Med"},{"key":"183_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2165\/11584490-000000000-00000","volume":"27","author":"NL Pratt","year":"2010","unstructured":"Pratt NL, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series. Drugs Aging. 2010;27:885\u201393. 10.2165\/11584490-000000000-00000 .","journal-title":"Drugs Aging"},{"key":"183_CR20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1533317510390351","volume":"26","author":"V Mittal","year":"2011","unstructured":"Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:10\u201328.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"183_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3238\/arztebl.2010.0543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt S, Schmiedl S, Th\u00fcrmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch \u00c4rztebl. 2010;107:543\u201351. 10.3238\/arztebl.2010.0543 .","journal-title":"Dtsch \u00c4rztebl"},{"key":"183_CR22","volume-title":"Categorical data analysis using SAS","author":"ME Stokes","year":"2012","unstructured":"Stokes ME, Davis C, Koch G. Categorical data analysis using SAS. 3rd ed. Cary: SAS Institute; 2012.","edition":"3"},{"key":"183_CR23","unstructured":"World Health Organization. Cancer pain relief. With a guide to opioid availability. 2nd ed. Geneva: WHO; 1996."},{"key":"183_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00228-016-2058-5","volume":"72","author":"M Gustafsson","year":"2016","unstructured":"Gustafsson M, Isaksson U, Karlsson S, Sandman PO, L\u00f6vheim H. Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013. Eur J Clin Pharmacol. 2016;72:987\u201394. 10.1007\/s00228-016-2058-5 .","journal-title":"Eur J Clin Pharmacol"},{"key":"183_CR25","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.3399\/bjgp16X685213","volume":"66","author":"CF Johnson","year":"2016","unstructured":"Johnson CF, Frei C, Downes N, McTaggart SA, Akram G. Benzodiazepine and z-hypnotic prescribing for older people in primary care: a cross-sectional population-based study. Br J Gen Pract. 2016;66:e410\u20135. 10.3399\/bjgp16X685213 .","journal-title":"Br J Gen Pract"},{"key":"183_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/pds.4123","volume":"26","author":"A B\u00e9nard-Laribi\u00e8re","year":"2017","unstructured":"B\u00e9nard-Laribi\u00e8re A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, et al. Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study. Pharmacoepidemiol Drug Saf. 2017;26:162\u20139. 10.1002\/pds.4123 .","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"183_CR27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91:1632\u20139. 10.1016\/j.mayocp.2016.07.024 .","journal-title":"Mayo Clin Proc"},{"key":"183_CR28","doi-asserted-by":"publisher","first-page":"e011908","DOI":"10.1136\/bmjopen-2016-011908","volume":"6","author":"S Heinemann","year":"2016","unstructured":"Heinemann S, Wei\u00df V, Straube K, Nau R, Grimmsmann T, Himmel W, Hummers-Pradier E. Understanding and reducing the prescription of hypnotics and sedatives at the interface of hospital care and general practice: a protocol for a mixed-methods study. BMJ Open. 2016;6:e011908. 10.1136\/bmjopen-2016-011908 .","journal-title":"BMJ Open"},{"key":"183_CR29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2318-9-30","volume":"9","author":"S Berdot","year":"2009","unstructured":"Berdot S, Bertrand M, Dartigues J-F, Fourrier A, Tavernier B, Ritchie K, Alp\u00e9rovitch A. Inappropriate medication use and risk of falls--a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009;9:30.","journal-title":"BMC Geriatr"},{"key":"183_CR30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/clpt.2011.44","volume":"89","author":"PF Gallagher","year":"2011","unstructured":"Gallagher PF, O\u2019Connor MN, O\u2019Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP\/START criteria. Clin Pharmacol Ther. 2011;89:845\u201354.","journal-title":"Clin Pharmacol Ther"},{"key":"183_CR31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4212\/cjhp.v67i6.1405","volume":"67","author":"E Francis","year":"2014","unstructured":"Francis E, Dyks D, Kanji S. Influence of admission to a tertiary care hospital after a fall on use of potentially inappropriate medications among older patients. Can J Hosp Pharm. 2014;67:429\u201335.","journal-title":"Can J Hosp Pharm"},{"key":"183_CR32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.12617","volume":"80","author":"K Ruxton","year":"2015","unstructured":"Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80:209\u201320.","journal-title":"Br J Clin Pharmacol"},{"key":"183_CR33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.1997.00440350031003","volume":"157","author":"MH Beers","year":"1997","unstructured":"Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157:1531\u20136.","journal-title":"Arch Intern Med"},{"key":"183_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/nur.20232","volume":"31","author":"DM Fick","year":"2008","unstructured":"Fick DM, Mion LC, Beers MH, L Waller J. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health. 2008;31:42\u201351. 10.1002\/nur.20232 .","journal-title":"Res Nurs Health"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-017-0183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:51:10Z","timestamp":1751071870000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-017-0183-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["183"],"URL":"https:\/\/doi.org\/10.1186\/s40360-017-0183-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"76"}}